Stifel Maintains Hold on Aclaris Therapeutics, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Alex Thompson has maintained a Hold rating on Aclaris Therapeutics (NASDAQ:ACRS) but has lowered the price target from $2 to $1.
December 18, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Stifel has maintained a Hold rating on Aclaris Therapeutics but reduced the price target from $2 to $1, indicating a potential downside or limited upside.
The reduction in price target by a reputable analyst like Stifel could lead to a negative investor sentiment in the short term, potentially causing the stock price to decrease as the new target suggests a lower valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100